Literature DB >> 32404635

Calciprotein particles: mineral behaving badly?

Edward R Smith1,2, Tim D Hewitson1,2, Willi Jahnen-Dechent3.   

Abstract

PURPOSE OF REVIEW: Calciprotein particles (CPP) are formed in supersaturated solutions of calcium, phosphate and the mineral-binding protein fetuin-A. CPP have garnered considerable interest as potential mediators of mineral stress, but little consideration has been given to their origin, clearance and role in metabolism. RECENT
FINDINGS: CPP are made whilst buffering the mineral absorbed from the intestine after a meal or during remodelling of bone matrix. The postprandial rise in circulating CPP rise may be sensed by osteoblasts/osteocytes in bone, stimulating the secretion of the master phosphatonin fibroblast growth factor 23. Amorphous calcium phosphate-containing CPP are rapidly cleared by endothelial cells in the liver whereas crystalline apatite-containing CPP are filtered by phagocytic cells of the reticuloendothelial system. Impaired excretory function in kidney disease may lead to accumulation of CPP and its precursors with possible pathological sequalae. Inability to stabilize CPP in fetuin-A-deficiency states can result in intraluminal precipitation and inflammatory cascades if other mineralisation regulatory networks are compromised.
SUMMARY: CPP allow efficient transport and clearance of bulk calcium phosphate as colloids without risk of precipitation. As circulating factors, CPP may couple dietary mineral exposure with endocrine control of mineral metabolism in bone, signalling the need to dispose of excess phosphate from the body.

Entities:  

Year:  2020        PMID: 32404635     DOI: 10.1097/MNH.0000000000000609

Source DB:  PubMed          Journal:  Curr Opin Nephrol Hypertens        ISSN: 1062-4821            Impact factor:   2.894


  6 in total

Review 1.  Phosphate Is a Cardiovascular Toxin.

Authors:  Maren Leifheit-Nestler; Isabel Vogt; Dieter Haffner; Beatrice Richter
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

2.  Effect of Sevelamer on Calciprotein Particles in Hemodialysis Patients: The Sevelamer Versus Calcium to Reduce Fetuin-A-Containing Calciprotein Particles in Dialysis (SCaRF) Randomized Controlled Trial.

Authors:  Edward R Smith; Fei Fei M Pan; Tim D Hewitson; Nigel D Toussaint; Stephen G Holt
Journal:  Kidney Int Rep       Date:  2020-06-29

3.  Effect of nutritional calcium and phosphate loading on calciprotein particle kinetics in adults with normal and impaired kidney function.

Authors:  Mark K Tiong; Michael M X Cai; Nigel D Toussaint; Sven-Jean Tan; Andreas Pasch; Edward R Smith
Journal:  Sci Rep       Date:  2022-05-05       Impact factor: 4.996

Review 4.  Inflammation: a putative link between phosphate metabolism and cardiovascular disease.

Authors:  Jakob Voelkl; Daniela Egli-Spichtig; Ioana Alesutan; Carsten A Wagner
Journal:  Clin Sci (Lond)       Date:  2021-01-15       Impact factor: 6.124

5.  Calciprotein Particles Link Disturbed Mineral Homeostasis with Cardiovascular Disease by Causing Endothelial Dysfunction and Vascular Inflammation.

Authors:  Daria K Shishkova; Elena A Velikanova; Leo A Bogdanov; Maxim Yu Sinitsky; Alexander E Kostyunin; Anna V Tsepokina; Olga V Gruzdeva; Andrey V Mironov; Rinat A Mukhamadiyarov; Tatiana V Glushkova; Evgenia O Krivkina; Vera G Matveeva; Oksana N Hryachkova; Victoria E Markova; Yulia A Dyleva; Ekaterina V Belik; Alexey V Frolov; Amin R Shabaev; Olga S Efimova; Anna N Popova; Valentina Yu Malysheva; Roman P Kolmykov; Oleg G Sevostyanov; Dmitriy M Russakov; Viatcheslav F Dolganyuk; Anton K Gutakovsky; Yuriy A Zhivodkov; Anton S Kozhukhov; Elena B Brusina; Zinfer R Ismagilov; Olga L Barbarash; Arseniy E Yuzhalin; Anton G Kutikhin
Journal:  Int J Mol Sci       Date:  2021-11-18       Impact factor: 5.923

6.  Reduction of Calciprotein Particles in Adults Receiving Infliximab for Chronic Inflammatory Disease.

Authors:  Mark K Tiong; Edward R Smith; Nigel D Toussaint; Hasan F Al-Khayyat; Stephen G Holt
Journal:  JBMR Plus       Date:  2021-05-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.